Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBIT: 2017-2019

Historic EBIT for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' EBIT fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 29.80% down from last year.
  • Per Monopar Therapeutics' latest filing, its EBIT stood at -$1.2 million for Q4 2019, which was down 61.29% from -$759,448 recorded in Q3 2019.
  • Monopar Therapeutics' 5-year EBIT high stood at -$373,839 for Q1 2017, and its period low was -$14.9 million during Q3 2017.
  • For the 3-year period, Monopar Therapeutics' EBIT averaged around -$2.0 million, with its median value being -$828,354 (2018).
  • Examining YoY changes over the last 5 years, Monopar Therapeutics' EBIT showed a top increase of 95.52% in 2018 and a maximum decrease of 140.01% in 2018.
  • Over the past 3 years, Monopar Therapeutics' EBIT (Quarterly) stood at -$736,800 in 2017, then decreased by 25.73% to -$926,358 in 2018, then crashed by 32.23% to -$1.2 million in 2019.
  • Its last three reported values are -$1.2 million in Q4 2019, -$759,448 for Q3 2019, and -$932,109 during Q2 2019.